Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2007, Vol. 18 ›› Issue (4): 227 doi: 10.1016/S1001-8042(07)60051-7

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Dosimetry of chimeric TNT in lung tumor patients

CHEN Yangchun1,2 CHEN Shaoliang1* JU Dianwen3 SHI Hongcheng1 YAO Zhifeng1   

  1. 1 Nuclear Medicine Department, Zhongshan Hospital, Fudan University, Shanghai 200032, China;
    2 PET/CT Center of the First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510230, China;
    3 Shanghai MediPharm Biotech Co, Ltd, Shanghai 201203, China
PDF ShareIt Export Citation
CHEN Yangchun CHEN Shaoliang JU Dianwen SHI Hongcheng YAO Zhifeng. Dosimetry of chimeric TNT in lung tumor patients.Nuclear Science and Techniques, 2007, 18(4): 227     doi: 10.1016/S1001-8042(07)60051-7
Citations
Altmetrics

Abstract: The purpose of this study was to assess the absorbed dose of tumor and main critical organs in 131I labeled chimeric tumor necrotic treatment (chTNT). In 9 patients, a single intravenous dose of (29.6±3.7) MBq/kg was administered. Blood samples were drawn at different time intervals, and urine was collected for up to one week. Tissue distribution of 131I –chTNT was followed for up to one week by gamma camera imaging. Absorbed doses to the whole body and to normal organs were computed according to the MIRD scheme using Mirdose-3 software. S-factors for lung tumors were estimated by comparison with lungs of similar mass and position in the body. It was found that mean serum disappearance half time values for 131I-chTNT were (4.93±9.36) h and (61.7±21.2) h for α, β respectively, while that for whole body was(99±10) h. Mean urine biological clearance half time value was (90±10) h. The absorbed dose to tumor was (8.28±2.65) Gy, and the tumor

Key words: Radioimmunotherapy, Radiation dosage, Iodine radioisotopes